Gilead Q3 revenue rise bolstered by $873m Veklury sales

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that a

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.  

CureVac claims €75m in EU funding for mRNA COVID-19 vaccine

German vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost its manufacturing capacity for its potential COVID-19 vaccine.

Royalty Pharma shares surge 59% after $2.2 billion IPO

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s

Celgene investors’ CVR payment looks rocky, as FDA rejects i...

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft

COVID-19 candidate Actemra helps Roche to solid first quarte...